ILAP Performance Metrics and Innovation Passport list
Updated 5 August 2026
© Crown copyright 2026
This publication is licensed under the terms of the Open Government Licence v3.0 except where otherwise stated. To view this licence, visit nationalarchives.gov.uk/doc/open-government-licence/version/3 or write to the Information Policy Team, The National Archives, Kew, London TW9 4DU, or email: psi@nationalarchives.gov.uk.
Where we have identified any third party copyright information you will need to obtain permission from the copyright holders concerned.
This publication is available at https://www.gov.uk/government/publications/innovative-licensing-and-access-pathway-ilap/ilap-performance-metrics-and-innovation-passport-list
ILAP Quarterly Update - August 2026
In round four, two eligible applications progressed to full assessment by the ILAP Application Review Panel. Following assessment against the published selection criteria, both applications demonstrated sufficiently strong evidence across all three selection criteria and were awarded an Innovation Passport (IP).
Innovation Passport metrics (as of August 2026)
Applications
| Eligible applications received (cumulative) | 21 |
Outcomes
| Innovation Passports awarded | 5 |
| Innovation Passports withdrawn | 0 |
Performance metrics
| Number of IP outcomes delivered within expected timeframes | 21 out of 21 (100%) |
| Number of TDPs delivered within 6 months of IP award | 3 out of 3 (100%) |
ILAP success metrics
The overarching goal of the Innovative Licensing and Access Pathway (ILAP) is to reduce the time to patient access for transformative new medicines and drug-device combinations in the UK.
Medicines development spans several years and the number of ILAP products will initially be small. ILAP success is therefore tracked using a staged set of measures:
- early measures focus on stakeholder experience and perceived value
- time‑to‑milestone measures are reported as products progress through regulatory and HTA stages
- adoption measures will be added as the approach is finalised and data sources mature.
Experience and perceived value
| Measure |
|---|
| Feedback from IP holders via surveys (including testimonials and case studies), and from the independent ILAP advisory groups |
| ≥80% of IP holder survey respondents report satisfaction with ILAP |
Timelines
| Metric category | Metric |
|---|---|
| End-to-end timelines : | Time (days) from Marketing Authorisation Application (MAA) to first HTA final guidance for ILAP products, compared with non‑ILAP products |
| Regulatory timelines: | Time (days) from MAA to Marketing Authorisation (MA) grant for ILAP products, compared with non‑ILAP products |
| HTA timelines: | Time (days) from Health Technology Assessment (HTA) submission to first HTA final guidance for ILAP products, compared with non‑ILAP products |
HTA timelines refer to first final guidance only (excluding resubmissions).
Innovation Passport list
Download the latest Innovation Passport list